BridgeBio Pharma, Inc. · NASDAQ:BBIO
BridgeBio Pharma, Inc. shareholders
As of Sep 30, 2026, 458 institutions reported holding BridgeBio Pharma, Inc., 98.5% of its shares. Largest: Vanguard, Janus Henderson and Farallon Capital Management, L.L.C. New holders, exits, insiders and big stakes, each with its filing.
| Holder | Shares | % of BridgeBio Pharma, Inc. | Change | Filed |
|---|---|---|---|---|
| Vanguard | 16.8M | 8.6% | −135K | Nov 16, 2026 |
| Janus Henderson | 14.6M | 7.5% | first report | Nov 16, 2026 |
| Farallon Capital Management, L.L.C. | 14.2M | 7.3% | +3.5M | Nov 16, 2026 |
| BlackRock | 10.4M | 5.3% | +102K | Nov 13, 2026 |
| Viking Global Investors LP | 9.79M | 5.0% | −157K | Nov 16, 2026 |
| Wellington | 9.46M | 4.9% | +4.15M | Nov 16, 2026 |
| Kohlberg Kravis Roberts & Co. L.P. | 8.26M | 4.2% | −5M | Nov 13, 2026 |
| State Street | 4.98M | 2.6% | +541K | Nov 12, 2026 |
| Invesco | 4.32M | 2.2% | +616K | Nov 12, 2026 |
| Franklin Templeton | 4.15M | 2.1% | +995K | Nov 12, 2026 |